The case of multiple changes in genetically engineered biological therapy in a child with juvenile idiopathic arthritis

A clinical case of multiple changes in genetic engineering biological therapy in a child with juvenile idiopathic arthritis is presented. A detailed study of this pathology in recent years is associated with an increase in morbidity among the child population, as well as a large number of prognostically unfavorable outcomes of the disease. Particular progress has been made through the use of new approaches in the treatment of arthritis in children. Currently, the use of genetic engineering therapy in the treatment of rheumatic diseases is a highly effective method for reducing disability and improving the quality of life of patients. But at the same time, the issue of starting therapy, choosing a group of biologically active drugs and their timely change in the absence of effect remains relevant. A feature of this clinical case is the timely change in treatment tactics with repeated changes in the class of genetically engineered drugs. Over several years of using GIBP, 6 drugs were used that gave a positive, but short-term effect.